Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA lifts clinical hold on Merck KGaA's Stimuvax cancer vaccine study

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Merck KGaA and U.S. affiliate EMD Serono will resume two studies of experimental cancer immunotherapy Stimuvax (BLP liposome vaccine) in patients with non-small cell lung cancer after FDA partially lifted the clinical hold it placed on the entire Stimuvax program in March (1"The Pink Sheet" DAILY, March 23, 2010). A third study, STRIDE, in advanced breast cancer, remains on hold while Merck and the agency decide on next steps, Merck said June 17. The hold followed a case of encephalitis observed in a patient enrolled in an exploratory Phase II trial of the vaccine in patients with multiple myeloma. Protocol in the two NSCLC trials, START and INSPIRE, are being amended to add specific safety measures in response to the serious adverse event

You may also be interested in...



Merck KGaA Cancer Vaccine Studies On Clinical Hold Because Of Encephalitis, But AE Isn't In Lead Indications

The single event occurred in an exploratory study with a very different patient population and regimen than Phase III trials of the vaccine against lung and breast cancers, leaving hope the setback will be short-lived.

AAM Welcomes Proposal To Update Medicare Part D

After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.

Dr Reddy’s Wants To Break Into Top Five In India

Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel